en · de · es · fr · pt
selank-notes.peptides9002.com › Blog › Selank Background And Chemical Identity — Questions and Answers

Selank Background And Chemical Identity — Questions and Answers

By Editorial Desk · published 2026-03-07 · last reviewed 2026-04-10 · Blog

The short version of GABA-A receptor fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-04-10. Anything still debated is marked as such rather than presented as settled.

Selank Background And Chemical Identity

The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.

Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.

Mechanism and Evidence Base

Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.

Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.

Selank at a glance

PropertyValueNotes
Molecular classSynthetic heptapeptideStabilized analog of tuftsin
SequenceThr-Lys-Pro-Arg-Pro-Gly-ProSingle-letter form: TKPRPGP
Molecular formulaC33H57N11O9Monoisotopic mass about 751.9 Da
AppearanceWhite to off-white powderTypically supplied as lyophilized solid
SolubilityFreely soluble in waterAlso soluble in common polar solvents

Stability, Handling, and Analytical Control

Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.

Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.

Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.

Related pages on this site

Selank Handling, Stability, and Analysis

Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.

Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.

Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.

Peptide Identity and Structure

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.

Supporting material

==== Financing residency programs ==== The US Department of Health and Human Services, primarily Medicare, funds the vast majority of residency training in the US. This tax-based financing covers resident salaries and benefits through payments called Direct Medical Education, or DME, payments. Medicare also uses taxes for Indirect Medical Education, or IME payments, a subsidy paid to teaching hospitals that is tied to admissions of Medicare patients in exchange for training resident physicians in certain selected specialties. Overall funding levels, however, have remained frozen over the last ten years, creating a bottleneck in the training of new physicians in the US, according to the AMA. On the other hand, some argue that Medicare subsidies for training residents simply provide surplus revenue for hospitals, which recoup their training costs by paying residents salaries that are far below the residents' market value. Nicholson concludes that residency bottlenecks are not caused by a Medicare funding cap, but rather by Residency Review Committees (which approve new residencies in each specialty), which seek to limit the number of specialists in their field to maintain high incomes. In any case, hospitals trained residents long before Medicare provided additional subsidies for that purpose. A large number of teaching hospitals fund resident training to increase the supply of residency slots, leading to the modest 4% total growth in slots from 1998 to 2004.

== Medical uses == Z-drugs are used for the short-term treatment of insomnia where difficulty with sleep initiation or sleep maintenance are prominent symptoms. Long-term use is not recommended, as tolerance, dependence, and addiction can occur. Z-drugs decrease sleep latency by 10 to 20 minutes. However, no Z-drug has shown clinically significant increase in total sleep time which is defined as at least 30 minutes. Tolerance develops within days to weeks. The risk of developing tolerance with Z-drugs is comparable to benzodiazepines. Z-drugs are recommended to be taken at the lowest effective dose, with a duration of 2–3 weeks, for short-term insomnia. Use of Z-drugs more than 4 weeks is not recommended. Caution must be taken when Z-drugs are used in conjunction with benzodiazepines, sedatives, alcohol or other drugs affecting the central nervous system. Cognitive behavioral therapy has been found to be superior to Z-drugs in the treatment of insomnia and has been found to have lasting effects on sleep quality for at least a year after therapy. A 2004 meta-analysis of randomised controlled clinical trials that compared benzodiazepines to Z-drugs found few clear and consistent differences between zopiclone and the benzodiazepines in sleep onset latency, total sleep duration, number of awakenings, quality of sleep, adverse events, tolerance, rebound insomnia, and daytime alertness.

The earliest form of curing is drying, which has been in use since ancient times, the earliest known practice dates back to 12,000 B.C. by inhabitants of the modern Asian and Middle Eastern regions. Water is traditionally removed through evaporation by using methods such as air drying, sun drying, smoking or wind drying, although today electric food dehydrators can be used to speed the drying process and ensure more consistent results.

Sources: en.wikipedia.org

Notes from published material

Biochemists or biological chemists are scientists who are trained in biochemistry. They study chemical processes and chemical transformations in living organisms. Biochemists study DNA, proteins and cell parts. Biochemists also research how certain chemical reactions happen in cells and tissues and observe and record the effects of products in food additives and medicines. Biochemist researchers focus on planning and constructing research experiments, mainly for developing new products, updating existing products and analyzing said products. It is also the responsibility of a biochemist to present their research findings and create grant proposals to obtain funds for future research. Biochemists study aspects of the immune system, the expressions of genes, isolating, analyzing, and synthesizing different products, mutations that lead to cancers, and manage laboratory teams and monitor laboratory work. Biochemists also have to have the capabilities of designing and building laboratory equipment and devise new methods of producing correct results for products. The most common industry role is the development of biochemical products and processes. Identifying substances' chemical and physical properties in biological systems is of great importance, and can be carried out by doing various types of analysis. Biochemists must also prepare technical reports after collecting, analyzing and summarizing the information and trends found. In biochemistry, researchers often break down complicated biological systems into their component parts.

=== Sequence motif === Short amino acid sequences within proteins often act as recognition sites for other proteins. For instance, SH3 domains typically bind to short PxxP motifs (i.e. 2 prolines [P], separated by two unspecified amino acids [x], although the surrounding amino acids may determine the exact binding specificity). Many such motifs has been collected in the Eukaryotic Linear Motif (ELM) database.

Ampicillin Amoxicillin There are many ampicillin precursors in existence. These are inactive compounds that are broken down in the gut to release ampicillin. None of these pro-drugs of ampicillin is in current use:

Big Drawer II (ビグドローワー2, Bigu Dorōwā Tsū): A chest-of-drawers-themed Super Kaijuki that he uses in his smear campaign against the Dekarangers before it is destroyed by Deka Base Robo. Abtrex (アブトレックス, Abutorekkusu): Abrella's personal Kaijuki that can assume the Abtrailer (アブトレーラー, Abutorērā) drill-vehicle mode. He tasks the Alienizer Angorl with using it to attack the Deka Base and damage Dekaranger Robo before the Kaijuki is destroyed by Deka Bike Robo and the Deka Wing Cannon. During the events of the crossover film Mahō Sentai Magiranger vs. Dekaranger, Agent X pilots the succeeding model, Abotrex (アボトレックス, Abotorekkusu), before it is blasted into space by Magi Legend and the Deka Wing Cannon and destroyed by Magi King, Dekaranger Robo, Travelion, and Deka Bike Robo. Abrella is voiced by Ryūsei Nakao (中尾 隆聖, Nakao Ryūsei).

Sources: en.wikipedia.org

Frequently asked questions

What is Selank?

Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.

Where was Selank developed?

It was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, during the 1990s. Most published research originates from Russian institutions. Independent international replication remains limited.

How does Selank differ from tuftsin?

Tuftsin is a natural tetrapeptide with the sequence Thr-Lys-Pro-Arg that participates in immune signaling. Selank extends that sequence with Pro-Gly-Pro at the C-terminus. The added residues are linked to greater resistance to enzymatic breakdown.

What mechanisms are proposed for Selank?

Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.

Network